For research use only
| Cat No. | ABL-TC0325 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphoblast-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Product Code | KASUMI-3; KASUMI3; Kasumi3 |
Kasumi-3 Cell Line is a human myeloblast leukemia model, derived from MPO-negative acute leukemia, supporting hematology and cancer biology studies.
Kasumi-3 is a human human lymphoblast cell line derived from the peripheral blood of a 57-year-old Asian male patient with acute myeloblastic leukemia (AML) M0 subtype. These suspension cells exhibit a blast-like morphology typical of leukemic progenitors and can be continuously cultured in vitro. Kasumi-3 cell line exhibits a complex and hypodiploid karyotype with multiple chromosomal abnormalities typical of acute myeloid leukemia. They are characterized by the chromosomal translocation t(3;7)(q27;q22), leading to the activation of the EVI1 gene, which encodes a zinc-finger transcription factor involved in hematopoiesis. Additional chromosomal abnormalities include del(5)(q15), del(9)(q32), and add(12)(p11). Kasumi-3 express hematopoietic and myeloid markers such as CD13, CD33, CD34, HLA-DR, and c-Kit, reflecting their immature myeloid origin. Kasumi-3 cells are widely used as a model for studying AML pathophysiology, differentiation therapy, and drug screening due to their genetic and phenotypic relevance to human AML.
| Product Code | KASUMI-3; KASUMI3; Kasumi3 |
| Species | Human |
| Cat.No | ABL-TC0325 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast-like |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
Kasumi-3 cells are a valuable model for research into acute myeloblastic leukemia (AML) and immune disorders. They are particularly useful for studying the M0 subtype of AML and investigating the role of the EVI1 gene in leukemogenesis. In addition, their suitability for 3D culture systems allows researchers to model complex tissue environments and explore innovative therapeutic strategies in hematological and immunological research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
